Table 2. Incremental cost effectiveness analysis: DCV/ASV versus PR and PIs considering two prices.
| Treatment strategy | Total drugCost ($US) | Total intervention cost ($US) | Total QALY | Incremental cost ($US) | Incremental QALY | ICER ($US/QALY) |
|---|---|---|---|---|---|---|
| PR | 11,040 | 17,803 | 10.9 | - | - | - |
| PIs | 30,335 | 34,599 | 12.3 | 16,796 | 1,40 | 11,977 |
| DCV/ASV | 77,419 | 80,117 | 14.6 | 45,518 | 2,3 | 19,790 |
| DCV/ASV | 58,065 | 60,775 | 14.6 | 26,176 | 2,3 | 11,380 |
| DCV/ASV | 38,710 | 41,856 | 14.6 | 7,257 | 2,3 | 3,155 |
PR: Peginterferon plus Ribavirin, PIs: Protease Inhibitors, DCV/ASV: Daclatasvir plus Asunaprevir, QALY: Quality Adjusted Life Years, ICER: Incremental cost effectiveness ratio, 1 $US = 620 CLP.